Atıf İçin Kopyala
EKENEL M., Karabulut S., Cil I., Zirtiloglu A., Aydin E., Tural D.
ACTAS UROLOGICAS ESPANOLAS, cilt.44, sa.1, ss.27-33, 2020 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
44
Sayı:
1
-
Basım Tarihi:
2020
-
Doi Numarası:
10.1016/j.acuro.2019.06.007
-
Dergi Adı:
ACTAS UROLOGICAS ESPANOLAS
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, Gender Studies Database, MEDLINE, DIALNET
-
Sayfa Sayıları:
ss.27-33
-
İstanbul Üniversitesi Adresli:
Evet
Özet
Introduction: Sunitinib (SUN) and pazopanib (PAZ) are 2 oral tyrosine kinase inhibitors against vascular endothelial growth factor. Their efficacy and safety in metastatic renal cell carcinoma has been proven with phase iii studies. However, real world data is limited. The objective of this study is to assess the clinical benefit of SUN and PAZ in routine practice.